Bispecific T-Cell Engagers Emerge as Later-Line Therapies for DLBCL
October 2nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Medhi H. Hamadani, MD, discussed the bispecific T-cell engagers epcoritamab and glofitamab and how they fit into the treatment algorithm for patients with diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.
Stereotactic Radiosurgery Plus Immunotherapy, Safe for Metastatic NSCLC
A recent phase 1/2 study revealed promising results, with an estimated 4-month intracranial progression-free survival rate of 70.7% with stereotactic radiosurgery with the combination of nivolumab and ipilimumab.
Forimtamig Shows Deep, Durable Responses in Relapsed/Refractory Multiple Myeloma
September 29th 2023At a median duration of response of 12.2 months, the objective response rates with forimtamig across all dose levels was 66.7% with a very good partial response rate of 54.2%, according to data from a phase 1a dose-escalation trial.
Real-World Study of Teclistamab Matches MajesTec-1 Efficacy Data in RRMM
September 29th 2023According to data presented at IMS 2023, a real-world analysis showed that teclistamab demonstrated comparable efficacy to the results observed in the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.
Desai on Embracing Curiosity and Change in the Oncology Field
September 29th 2023In the first episode of Emerging Experts, Aakash Desai, MD, MPH, discusses his journey through the oncology field by reminiscing on the encouraging guidance of his mentors, personal research goals, and his experiences thus far as an oncologist.
Considering Disease Risk Criteria When Choosing Systemic Therapy for Advanced RCC
September 29th 2023Combination therapies for patients with advanced renal cell carcinoma provides clinicians with new treatment avenues for their patients. To assess which path to go down, Tian Zhang, MD, MHS, and Randy F. Sweis, MD, led virtual discussions on evaluating patients’ risk criteria to determine their proper treatment.